W. Mark Saltzman

Last updated
W. Mark Saltzman
Born (1959-09-08) September 8, 1959 (age 64)
NationalityAmerican
Alma mater Iowa State University
Massachusetts Institute of Technology
Scientific career
Fields Biomedical Engineering
Institutions Johns Hopkins
Cornell University
Yale University
Doctoral advisor Robert S. Langer

William Mark Saltzman was named the Goizueta Foundation Professor of Biomedical and Chemical Engineering at Yale University on July 1, 2002 and became the founding chair of Yale's Department of Biomedical Engineering in 2003. [1] Saltzman's research aims to promote new methods for drug delivery and develop new biotechnologies to combat human disease. A pioneer in the fields of biomaterials, nanobiotechnology, and tissue engineering, Saltzman has contributed to the design and implementation of a number of clinical technologies that have become essential to medical practice today. [2] His popular course Frontiers of Biomedical Engineering is available to everyone through Open Yale Courses.

Contents

Biography

Saltzman received a B.S. in Chemical Engineering in 1981 from Iowa State University, followed by a M.S. in Chemical Engineering in 1984 and a Ph.D. in Medical Engineering in 1987, both at the Massachusetts Institute of Technology. [3]

As a graduate student at the Massachusetts Institute of Technology (MIT), Saltzman built scaffolds that could be seeded with cells to sculpt new replacement tissues. He also created drug-impregnated implants from polymers that slowly and steadily release medicines for long periods—work that now helps patients in the form of GLIADEL, a chemotherapy-loaded polymer wafer that neurosurgeons implant in the brain to combat glioblastoma multiforme (GBM), one of the most aggressive types of malignant brain tumors. [4]

Discovering the Gliadel Wafer Gliadel Wafer.jpg
Discovering the Gliadel Wafer

He was appointed Assistant Professor of Chemical Engineering at Johns Hopkins University in 1987 and received a joint appointment in the Department of Biomedical Engineering at The Johns Hopkins School of Medicine in 1990. He was promoted to Associate Professor in 1992 and to Professor in 1995. In 1996, he moved to Cornell University, holding the first BP Amoco/H. Laurance Fuller Chair in Chemical Engineering.

He joined the faculty at Yale University, as the Goizueta Foundation Professor of Chemical and Biomedical Engineering, in July 2002 and became the first chair of Yale's Department of Biomedical Engineering in 2003. Since he arrived at Yale in 2002 to form the new department, he has seen his faculty group grow to 19 members. He hired slowly, knowing that each new person would have a significant effect on the overall department culture. Saltzman settled on four areas to excel in: imaging, biomolecular engineering, biomechanics, and systems biology. The department has developed largely as its founders envisioned—multidisciplinary, collegial, integrated with the medical school, and committed to undergraduate education. [5]

As of July 1, 2016, Saltzman serves as Head of Jonathan Edwards College at Yale University. [6]

Research

Saltzman's research focuses on developing the most economical, transportable and accessible methods for disease prevention and methods to more effectively deliver chemotherapy to the most aggressive forms of brain tumors. Dr. Saltzman's research interests include controlled drug delivery to the brain, polymers for supplementing or stimulating the immune system, cell interactions with polymers, and tissue engineering. He studies how to create safer and more effective medical and surgical therapy based on tissue engineering. Dr. Saltzman worked with an interdisciplinary team to develop what is now the standard of care for treating brain tumors. [7] [8]

Awards and honors

Committed to Undergraduate Teaching Committed to Undergraduate Teaching.jpg
Committed to Undergraduate Teaching

Works

Books

Selected Publications

SEM image of nanoparticles Nanoparticle.jpg
SEM image of nanoparticles

Related Research Articles

Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials.

<span class="mw-page-title-main">Hydrogel</span> Soft water-rich polymer gel

A hydrogel is a biphasic material, a mixture of porous, permeable solids and at least 10% by weight or volume of interstitial fluid composed completely or mainly by water. In hydrogels the porous permeable solid is a water insoluble three dimensional network of natural or synthetic polymers and a fluid, having absorbed a large amount of water or biological fluids. These properties underpin several applications, especially in the biomedical area. Many hydrogels are synthetic, but some are derived from nature. The term 'hydrogel' was coined in 1894.

<span class="mw-page-title-main">Robert S. Langer</span> American scientist

Robert Samuel Langer Jr. FREng is an American biotechnologist, businessman, chemical engineer, chemist, and inventor. He is one of the twelve Institute Professors at the Massachusetts Institute of Technology.

<span class="mw-page-title-main">Nanobiotechnology</span> Intersection of nanotechnology and biology

Nanobiotechnology, bionanotechnology, and nanobiology are terms that refer to the intersection of nanotechnology and biology. Given that the subject is one that has only emerged very recently, bionanotechnology and nanobiotechnology serve as blanket terms for various related technologies.

<span class="mw-page-title-main">Nanochemistry</span> Combination of chemistry and nanoscience

Nanochemistry is an emerging sub-discipline of the chemical and material sciences that deals with the development of new methods for creating nanoscale materials. The term "nanochemistry" was first used by Ozin in 1992 as 'the uses of chemical synthesis to reproducibly afford nanomaterials from the atom "up", contrary to the nanoengineering and nanophysics approach that operates from the bulk "down"'. Nanochemistry focuses on solid-state chemistry that emphasizes synthesis of building blocks that are dependent on size, surface, shape, and defect properties, rather than the actual production of matter. Atomic and molecular properties mainly deal with the degrees of freedom of atoms in the periodic table. However, nanochemistry introduced other degrees of freedom that controls material's behaviors by transformation into solutions. Nanoscale objects exhibit novel material properties, largely as a consequence of their finite small size. Several chemical modifications on nanometer-scaled structures approve size dependent effects.

<span class="mw-page-title-main">Drug delivery</span> Methods for delivering drugs to target sites

Drug delivery refers to approaches, formulations, manufacturing techniques, storage systems, and technologies involved in transporting a pharmaceutical compound to its target site to achieve a desired therapeutic effect. Principles related to drug preparation, route of administration, site-specific targeting, metabolism, and toxicity are used to optimize efficacy and safety, and to improve patient convenience and compliance. Drug delivery is aimed at altering a drug's pharmacokinetics and specificity by formulating it with different excipients, drug carriers, and medical devices. There is additional emphasis on increasing the bioavailability and duration of action of a drug to improve therapeutic outcomes. Some research has also been focused on improving safety for the person administering the medication. For example, several types of microneedle patches have been developed for administering vaccines and other medications to reduce the risk of needlestick injury.

Targeted drug delivery, sometimes called smart drug delivery, is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult, and the reduced ability to adjust the dosages.

<span class="mw-page-title-main">Nanofabrics</span> Textiles engineered with small particles that give ordinary materials advantageous properties

Nanofabrics are textiles engineered with small particles that give ordinary materials advantageous properties such as superhydrophobicity, odor and moisture elimination, increased elasticity and strength, and bacterial resistance. Depending on the desired property, a nanofabric is either constructed from nanoscopic fibers called nanofibers, or is formed by applying a solution containing nanoparticles to a regular fabric. Nanofabrics research is an interdisciplinary effort involving bioengineering, molecular chemistry, physics, electrical engineering, computer science, and systems engineering. Applications of nanofabrics have the potential to revolutionize textile manufacturing and areas of medicine such as drug delivery and tissue engineering.

Thiolated polymers – designated thiomers – are functional polymers used in biotechnology product development with the intention to prolong mucosal drug residence time and to enhance absorption of drugs. The name thiomer was coined by Andreas Bernkop-Schnürch in 2000. Thiomers have thiol bearing side chains. Sulfhydryl ligands of low molecular mass are covalently bound to a polymeric backbone consisting of mainly biodegradable polymers, such as chitosan, hyaluronic acid, cellulose derivatives, pullulan, starch, gelatin, polyacrylates, cyclodextrins, or silicones.

A nanogel is a polymer-based, crosslinked hydrogel particle on the sub-micron scale. These complex networks of polymers present a unique opportunity in the field of drug delivery at the intersection of nanoparticles and hydrogel synthesis. Nanogels can be natural, synthetic, or a combination of the two and have a high degree of tunability in terms of their size, shape, surface functionalization, and degradation mechanisms. Given these inherent characteristics in addition to their biocompatibility and capacity to encapsulate small drugs and molecules, nanogels are a promising strategy to treat disease and dysfunction by serving as delivery vehicles capable of navigating across challenging physiological barriers within the body. 

<span class="mw-page-title-main">Samir Mitragotri</span> American chemist (born 1971)

Samir Mitragotri is an Indian American professor at Harvard University, an inventor, an entrepreneur, and a researcher in the fields of drug delivery and biomaterials. He is currently the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences and the Wyss Institute for Biologically Inspired Engineering. Prior to 2017, he was the Duncan and Suzanne Mellichamp Chair Professor at University of California, Santa Barbara.

Nanoparticles for drug delivery to the brain is a method for transporting drug molecules across the blood–brain barrier (BBB) using nanoparticles. These drugs cross the BBB and deliver pharmaceuticals to the brain for therapeutic treatment of neurological disorders. These disorders include Parkinson's disease, Alzheimer's disease, schizophrenia, depression, and brain tumors. Part of the difficulty in finding cures for these central nervous system (CNS) disorders is that there is yet no truly efficient delivery method for drugs to cross the BBB. Antibiotics, antineoplastic agents, and a variety of CNS-active drugs, especially neuropeptides, are a few examples of molecules that cannot pass the BBB alone. With the aid of nanoparticle delivery systems, however, studies have shown that some drugs can now cross the BBB, and even exhibit lower toxicity and decrease adverse effects throughout the body. Toxicity is an important concept for pharmacology because high toxicity levels in the body could be detrimental to the patient by affecting other organs and disrupting their function. Further, the BBB is not the only physiological barrier for drug delivery to the brain. Other biological factors influence how drugs are transported throughout the body and how they target specific locations for action. Some of these pathophysiological factors include blood flow alterations, edema and increased intracranial pressure, metabolic perturbations, and altered gene expression and protein synthesis. Though there exist many obstacles that make developing a robust delivery system difficult, nanoparticles provide a promising mechanism for drug transport to the CNS.

Molly S. Shoichet, is a Canadian science professor, specializing in chemistry, biomaterials and biomedical engineering. She was Ontario's first Chief Scientist. Shoichet is a biomedical engineer known for her work in tissue engineering, and is the only person to be a fellow of the three National Academies in Canada.

<span class="mw-page-title-main">Andreas Bernkop-Schnürch</span> Austrian university teacher (born 1965)

Andreas Bernkop-Schnürch is an Austrian pharmaceutical technologist, scientist, pharmacist, entrepreneur, inventor and professor at the Institute of Pharmacy, University of Innsbruck. His research centers on the areas of pharmaceutical sciences, drug delivery, controlled release, bionanotechnology and polymer engineering. He is the inventor of various technologies such as thiolated polymers for that he coined the name thiomers in 2000 and phosphatase triggered charge converting nanoparticles for mucosal drug delivery. From 2016 to 2018 he served as a member of the Scientific Committee of the Innovative Medicines Initiative (IMI) of the European Union in Brussels giving advice on scientific priorities to be included in the Strategic Research Agenda for Horizon 2020. Since 2014 he is on the scientific advisory board of the Nicotine Science Center, Denmark. Andreas Bernkop-Schnürch is the founder of Mucobiomer Biotechnologische Forschungs- und Entwicklungs GmbH, Thiomatrix Forschungs- und Beratungs GmbH and Green River Polymers Forschungs und Entwicklungs GmbH. He is listed as a Highly Cited Researcher of the Institute of Scientific Information.

Mauro Ferrari is a nanoscientist and leader in the field of nanomedicine. He served as special expert on nanotechnology for the National Cancer Institute (2003-2005) and was instrumental in establishing the Alliance for Nanotechnology in Cancer in 2004. On 1 January 2020, Ferrari was made president of the European Research Council (ERC). Following a vote of no confidence, on 27 March 2020, "all 19 active members of the ERC’s Scientific Council individually and unanimously requested that Mauro Ferrari resign from his position as ERC’s President", due to poor conduct in office, exploiting the position to further his own projects, and for consistently failing to represent the interests of the ERC. On 7 April 2020, Ferrari officially resigned, stating to the media that he was "extremely disappointed by the European response” to the pandemic and expressing frustration over opposition to his efforts to launch a scientific program to combat the virus.

<span class="mw-page-title-main">Joseph Kost</span> Chemical engineering researcher

Joseph Kost is an Israeli academic, currently holder of The Abraham and Bessie Zacks Chair in Biomedical Engineering and the past Dean of the Faculty of Engineering Sciences at the Ben-Gurion University of the Negev.

<span class="mw-page-title-main">Antonios Mikos</span> Greek-American biomedical engineer

Antonios Georgios Mikos is a Greek-American biomedical engineer who is the Louis Calder Professor of Bioengineering and Chemical and Biomolecular Engineering at Rice University. He specialises in biomaterials, drug delivery, and tissue engineering.

<span class="mw-page-title-main">Joyce Wong</span> American engineer and professor

Joyce Y. Wong is an American engineer who is Professor of Biomedical Engineering and Materials Science and Engineering at Boston University. Her research develops novel biomaterials for the early detection treatment of disease. Wong is the Inaugural Director of the Provost's Initiative to promote gender equality and inclusion in STEM at all levels: Advance, Recruit, Retain and Organize Women in STEM. She is a Fellow of the American Association for the Advancement of Science, American Institute for Medical and Biological Engineering and Biomedical Engineering Society.

<span class="mw-page-title-main">Mark Prausnitz</span>

Mark Robert Prausnitz is an American chemical engineer, currently Regents’ Professor and J. Erskine Love, Jr. Chair in Chemical & Biomolecular Engineering at the Georgia Institute of Technology, He also serves as adjunct professor of biomedical engineering at Emory University and Adjunct Professor of Chemical & Biomolecular Engineering at the Korea Advanced Institute of Science and Technology. He is known for pioneering microneedle technology for minimally invasive drug and vaccine administration, which has found applications in transdermal, ocular, oral, and sustained release delivery systems.

Intranasal drug delivery occurs when particles are inhaled into the nasal cavity and transported directly into the nervous system. Though pharmaceuticals can be injected into the nose, some concerns include injuries, infection, and safe disposal. Studies demonstrate improved patient compliance with inhalation. Treating brain diseases has been a challenge due to the blood brain barrier. Previous studies evaluated the efficacy of delivery therapeutics through intranasal route for brain diseases and mental health conditions. Intranasal administration is a potential route associated with high drug transfer from nose to brain and drug bioavailability.

References